CTLA4 and cancer: Multiple ICIs were approved for cancer therapy such as nivolumab, pembrolizumab, and cemiplimab targeting programmed death-1 (PD-1) and ipilimumab targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (12).